Drug trafficking is a highly profitable commercial activity and remains a core business for organised crime groups across Europe today. Understanding the reality of the European drug market requires a holistic approach, following the supply chain from production and trafficking to distribution and use.
Taking such an approach, two EU agencies — the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol — have joined forces to provide their latest overview of the European illicit market for two stimulant drugs: cocaine and methamphetamine.
To be presented in Brussels on 6 May, the analyses combine data from the EMCDDA’s drug monitoring system with Europol’s operational intelligence on organised crime.
These are the first in a series of online modules exploring the EU drug market. Further modules will be published in 2023 to complete the strategic analysis. These will cover amphetamine, cannabis, heroin, MDMA and new psychoactive substances, as well as impacts, drivers and responses.
A news release, with the main highlights on cocaine and methamphetamine, will be available on 6 May.
Press conference
Date: 6 May 2022
Time: 10.30 Central European Time (CET/Brussels), 09.30 (WEST/Lisbon).
Venue: Résidence Palace, 155 Rue de la Loi, B-1040 Brussels (Polak room).
Registration and embargoed material: press@emcdda.europa.eu
The analyses will be available on 6 May at: www.emcdda.europa.eu and www.europol.europa.eu
Press contacts
EMCDDA press office:
press@emcdda.europa.eu
Tel. (351) 211 21 02 00 | (351) 935 994 027
Europol press office:
press@europol.europa.eu
Tel. (31) 703 02 50 01
The EMCDDA–Europol EU drug markets analysis is released every three years. The last report was published in 2019.
